Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
Ocugen (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has scheduled a conference call and live webcast for Friday, May 9, 2025, at 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and provide business updates.
The company will release its earnings announcement before the market opens on May 9. Investors can join via phone using U.S. dial-in (800) 715-9871 or international dial-in (646) 307-1963 with Conference ID 1773288. A webcast will be available on Ocugen's investor site, with a replay accessible for approximately 45 days after the event.
Ocugen (NASDAQ: OCGN), un'azienda biotecnologica specializzata in terapie geniche per malattie della cecità, ha programmato una conference call e una diretta webcast per venerdì 9 maggio 2025 alle 8:30 a.m. ET. L'evento tratterà i risultati finanziari del primo trimestre 2025 e fornirà aggiornamenti sull'attività aziendale.
L'azienda pubblicherà il comunicato sugli utili prima dell'apertura del mercato il 9 maggio. Gli investitori potranno partecipare telefonicamente chiamando il numero statunitense (800) 715-9871 o il numero internazionale (646) 307-1963 con ID conferenza 1773288. La diretta webcast sarà disponibile sul sito per investitori di Ocugen, con una replica accessibile per circa 45 giorni dopo l'evento.
Ocugen (NASDAQ: OCGN), una empresa biotecnológica especializada en terapias génicas para enfermedades de la ceguera, ha programado una conferencia telefónica y una transmisión en vivo para el viernes 9 de mayo de 2025 a las 8:30 a.m. ET. El evento cubrirá los resultados financieros del primer trimestre de 2025 y proporcionará actualizaciones comerciales.
La empresa publicará su anuncio de ganancias antes de la apertura del mercado el 9 de mayo. Los inversores pueden unirse por teléfono utilizando el número nacional (800) 715-9871 o el internacional (646) 307-1963 con ID de conferencia 1773288. La transmisión en vivo estará disponible en el sitio para inversores de Ocugen, con una repetición accesible aproximadamente durante 45 días después del evento.
Ocugen (NASDAQ: OCGN)은 실명 질환을 위한 유전자 치료에 특화된 바이오테크 기업으로, 2025년 5월 9일 금요일 오전 8시 30분 ET에 컨퍼런스 콜 및 라이브 웹캐스트를 예정하고 있습니다. 이번 행사에서는 2025년 1분기 재무 실적과 사업 현황 업데이트가 발표됩니다.
회사는 5월 9일 장 시작 전 실적 발표를 진행할 예정입니다. 투자자들은 미국 내 전화 (800) 715-9871 또는 국제 전화 (646) 307-1963를 통해 컨퍼런스 ID 1773288로 참여할 수 있습니다. 웹캐스트는 Ocugen 투자자 사이트에서 시청 가능하며, 행사 후 약 45일간 다시보기 서비스를 제공합니다.
Ocugen (NASDAQ : OCGN), une société de biotechnologie spécialisée dans les thérapies géniques pour les maladies de la cécité, a programmé une conférence téléphonique et une diffusion en direct pour le vendredi 9 mai 2025 à 8h30 ET. L'événement portera sur les résultats financiers du premier trimestre 2025 et fournira des mises à jour commerciales.
La société publiera son communiqué de résultats avant l'ouverture des marchés le 9 mai. Les investisseurs peuvent participer par téléphone en composant le numéro américain (800) 715-9871 ou le numéro international (646) 307-1963 avec l'ID de conférence 1773288. Une diffusion en direct sera disponible sur le site des investisseurs d'Ocugen, avec un replay accessible pendant environ 45 jours après l'événement.
Ocugen (NASDAQ: OCGN), ein Biotechnologieunternehmen, das sich auf Gentherapien für Erblindungskrankheiten spezialisiert hat, hat eine Telefonkonferenz und einen Live-Webcast für Freitag, den 9. Mai 2025, um 8:30 Uhr ET geplant. Die Veranstaltung wird die Finanzergebnisse des ersten Quartals 2025 sowie geschäftliche Updates behandeln.
Das Unternehmen wird die Gewinnmitteilung vor Markteröffnung am 9. Mai veröffentlichen. Investoren können telefonisch über die US-Einwahlnummer (800) 715-9871 oder die internationale Nummer (646) 307-1963 mit der Konferenz-ID 1773288 teilnehmen. Ein Webcast wird auf der Investorenseite von Ocugen verfügbar sein, mit einer Wiedergabe, die etwa 45 Tage nach der Veranstaltung abrufbar ist.
- None.
- None.
MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025.
Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 1773288
Webcast: Available on the events section of the Ocugen investor site
A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When will Ocugen (OCGN) report Q1 2025 earnings?
How can I join Ocugen's Q1 2025 earnings call?
What is Ocugen's (OCGN) main business focus?
How long will Ocugen's Q1 2025 earnings call replay be available?
